Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
21.43
+0.12 (0.56%)
At close: Mar 10, 2026, 4:00 PM EDT
21.25
-0.18 (-0.84%)
After-hours: Mar 10, 2026, 7:43 PM EDT
Denali Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
503
Market Cap
3.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 330.53M | 222.07M | 204.74% |
| Dec 31, 2022 | 108.46M | 59.80M | 122.90% |
| Dec 31, 2021 | 48.66M | -287.00M | -85.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Catalyst Pharmaceuticals | 588.99M |
| Tarsus Pharmaceuticals | 451.36M |
| Arcutis Biotherapeutics | 376.07M |
| IDEAYA Biosciences | 218.71M |
| Viridian Therapeutics | 70.85M |
| NewAmsterdam Pharma Company | 22.50M |
| Xenon Pharmaceuticals | 7.50M |
| Dianthus Therapeutics | 3.08M |
DNLI News
- 4 days ago - Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 4 days ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 12 days ago - Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 4 weeks ago - Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript - Seeking Alpha
- 4 weeks ago - Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™ - GlobeNewsWire
- 5 weeks ago - Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™ - GlobeNewsWire
- 5 weeks ago - Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™ - GlobeNewsWire
- 7 weeks ago - Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha